University College London Hospitals NHS
NHS Foundation Trust

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
September 2017

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (called Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 2 (2017/18) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of Sepember 2017.

For Further information on PID reporting, please visit the NIHR pages at:
http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm

Initiating Clinical Research – HRA Approval

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Date of First Patient Recruited	Benchmark Met	Reasons for delay correspond to:
1	16/WM/0437	206855	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer		05/10/2016	15/12/2016		26/01/2017		08/02/2017	28/02/2017	No	Sponsor
2	16/NE/0342	213304	A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)		11/10/2016	24/01/2017		02/02/2017		15/02/2017	05/04/2017	No	Sponsor
3	16/EE/0243	207331	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	22/09/2016	12/10/2016	01/08/2016		30/11/2016		20/12/2016	06/02/2017	No	Sponsor
4	16/SC/0271	187103	The UK Plasma based Molecular Profiling of Advanced Breast Cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multi parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening		12/10/2016	21/09/2016		27/01/2017		02/02/2017	09/03/2017	No	Sponsor

5	16/LO/1341	191779	A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease	01/09/2016	13/10/2016	14/10/2016		21/11/2016		23/11/2016	11/01/2017	No	Sponsor
6	16/LO/1312	188434	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400-211 in Patients with Dermatomyositis		13/10/2016	02/12/2016		13/01/2017		19/01/2017	17/05/2017	No	Sponsor
7	16/LO/1612	201997	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)	28/09/2016	17/10/2016	16/11/2016		14/12/2016		15/12/2016	06/01/2017	No	Sponsor
8	16/LO/1605	201385	HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours		25/10/2016			02/03/2017		08/03/2017	02/05/2017	No	Sponsor
9	16/SC/0304	166367	A Study into the Pharmacodynamic Biomarker Effects of Olaparib (a PARP Inhibitor) ± Degarelix (a GnRH antagonist) given Prior to Radical Prostatectomy		01/11/2016	16/08/2016		09/02/2017		10/02/2017		No	Sponsor
10	16/LO/1628	199315	The ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction.		01/11/2016	23/08/2016		21/02/2017		21/02/2017		No	Sponsor

11	16/LO/1636	172808	A prospective randomized multi-center study comparing endoscopic pneumodilation and per oral endoscopic myotomy (POEM) as treatment of idiopathic achalasia		03/11/2016	03/11/2016		27/01/2017		27/01/2017	31/03/2017	No	Sponsor
12	16/WM/0406	210454	Red cell transfusion in Acute myeloid Leukaemia	01/11/2016	10/11/2016	08/11/2016		12/12/2016		21/12/2016	15/06/2017	No	Neither
13	16/EM/0380	198726	A phase II, multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)		10/11/2016	09/11/2016		18/01/2017		20/01/2017	26/07/2017	No	Neither
14	16/LO/2008	208047	A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma	13/06/2016	15/11/2016	31/03/2017		03/05/2017		03/05/2017	05/05/2017	No	Sponsor
15	16/LO/1782	213379	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)		23/11/2016	29/11/2016		08/02/2017		09/02/2017	01/03/2017	No	Sponsor
16	16/LO/1436	205613	Evaluation of Potential Predictors of Disease Progression in Patients with aHUS including Genetics, Biomarkers, and Treatment.	14/09/2016	29/11/2016	29/11/2016		08/06/2017		12/06/2017	16/06/2017	No	Sponsor
17	16/SC/0418	198404	The clinical effectiveness of 5% Carbamide Plus, 10% Carbamide Plus compared to two commercially available 10% Carbamide peroxide products: a double blind randomised placebo controlled clinical trial		07/12/2016	07/12/2016		03/02/2017		22/02/2017	02/05/2017	No	Sponsor

18	16/LO/2106	215913	A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Patients with Solid Tumours and advanced gynaecologic cancers, with a focus on Ovarian Cancer	27/10/2016	09/12/2016	13/02/2017		29/03/2017		03/04/2017	07/04/2017	No	Sponsor
19	16/WM/0439	211177	A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)	17/06/2016	12/12/2016	12/12/2016		13/02/2017		07/04/2017	23/05/2017	No	Neither
20	16/SC/0566	213579	A PROSPECTIVE INTERNATIONAL MULTICENTRE RANDOMISED CONTROLLED SINGLE BLIND CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHAEMIC STROKE (MEDIS-INTERNATIONAL)		15/12/2016	10/01/2017		07/03/2017		07/03/2017		No	Sponsor
21	16/NE/0370	214375	A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids		06/01/2017	29/12/2016		14/03/2017		20/03/2017	22/06/2017	No	Sponsor
22	16/LO/1677	191232	A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis	27/10/2016	16/01/2017			18/04/2017		18/04/2017	16/05/2017	No	Sponsor
23	16/LO/1502	178292	Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer: CTC-STOP Trial	16/01/2017	16/01/2017	07/10/2016		02/05/2017		27/04/2017		No	Sponsor

24	16/LO/2186	188540	A randomised phase I/II study of Intensity Modulated Arc Therapy techniques in abdominal neuroblastoma		17/01/2017	17/01/2017		21/02/2017		21/02/2017	01/03/2017	Yes	
25	16/LO/1999	200065	A comparison of Cognitive Behaviour Therapy for insomnia (CBTi) and usual audiological rehabilitation in the management of tinnitus related insomnia		17/01/2017	09/02/2017		24/02/2017		24/02/2017	26/06/2017	No	Sponsor
26	16/LO/1776	191954	First-in-man feasibility study to assess the safety of TIPS microspheres in perianal fistulas		18/01/2017	17/01/2017		17/02/2017		17/02/2017	06/06/2017	No	Sponsor
27	17/SC/0033	218114	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma	11/10/2016	19/01/2017	29/03/2017		13/04/2017		13/04/2017	30/05/2017	No	Sponsor
28	17/LO/0011	217376	VEROnA: A pilot, open label, single-arm, window of opportunity study of vandetanib-eluting radio-opaque embolic beads (BTG 002814) in patients with resectable hepatocellular carcinoma and in patients with resectable liver malignancies	22/11/2016	19/01/2017	15/02/2017		08/05/2017		09/05/2017	11/08/2017	No	Sponsor

29	16/LO/2148	219354	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate- Risk Prostate Cancer that is Associated with an MRI Lesion	23/01/2017	24/01/2017			28/07/2017		31/07/2017	14/09/2017	No	Sponsor
30	16/LO/2150	201093	Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum–resistant ovarian cancer	25/11/2016	27/01/2017			12/05/2017		12/05/2017	25/07/2017	No	Sponsor
31	16/LO/1755	209250	Evaluation of the effect of Duodenal Mucosal Resurfacing (DMR) using the Revita System in the treatment of Type 2 diabetes (T2D)- Revita 2 – C-30000		31/01/2017	24/01/2017		01/03/2017		02/03/2017	28/04/2017	No	Neither
32	16/NE/0183	197040	Treatment of Poor-grade Subarachnoid Haemorrhage Trial 2	08/11/2016	31/01/2017	13/07/2016		25/04/2017		27/04/2017		No	Sponsor
33	17/LO/0247	213278	A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumour	26/10/2016	06/02/2017	24/05/2017		23/08/2017		24/08/2017	18/09/2017	No	Sponsor
34	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	14/11/2016	13/02/2017	21/04/2017		09/05/2017		26/05/2017	21/06/2017	No	Neither

35	17/LO/0284	221453	A study of single doses to evaluate the safety, tolerability, pharmacokinetics and target engagement of nebulised GSK3008348 in idiopathic pulmonary fibrosis patients, using positron emission tomography (PET) imaging	21/03/2017	15/02/2017			11/05/2017		12/05/2017	13/06/2017	No	Sponsor
36	16/LO/0986	202286	A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer	21/12/2016	16/02/2017	10/08/2016		05/04/2017		12/04/2017		No	Neither
37	16/WS/0197	186191	An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer	03/02/2017	16/02/2017			18/05/2017		02/06/2017	20/09/2017	No	Sponsor
38	16/LO/1004	207544	Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-inflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo-controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial	06/09/2016	20/02/2017			19/06/2017		22/06/2017		No	Sponsor
39	17/LO/0285	211245	Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer after Endocrine Failure	05/12/2016	24/02/2017	05/04/2017		15/05/2017		25/05/2017		No	Sponsor

40	16/SC/0376	202786	Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial		27/02/2017	10/10/2016		10/03/2017		13/03/2017	19/05/2017	No	Neither
41	17/NE/0058	219540	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors	24/02/2017	27/02/2017	13/04/2017		14/06/2017		14/06/2017	26/06/2017	No	Sponsor
42	16/SC/0590	191279	DEpletion of Serum amyloid P component In Alzheimer's Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer's disease	12/12/2016	02/03/2017	16/02/2017		09/05/2017		25/05/2017		No	Sponsor
43	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	10/02/2017	02/03/2017	03/01/2017		09/06/2017		16/06/2017		No	Sponsor
44	16/LO/2141	200571	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	26/01/2017	03/03/2017	06/04/2017		17/05/2017		29/06/2017	07/07/2017	No	Sponsor
45	17/NW/0175	222859	Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia	07/03/2017	06/03/2017			27/06/2017		27/06/2017	27/09/2017	No	Sponsor

46	17/EM/0032	209811	Reclassifying constipation using magnetic resonance imaging combined with high resolution manometry: a validation study and double-blind crossover trial (RECLAIM study)	09/12/2016	07/03/2017			20/04/2017		26/04/2017		No	Sponsor
47	16/LO/1960	199019	An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase	07/11/2016	07/03/2017	28/02/2017		07/03/2017		20/04/2017		No	Neither
48	17/WM/0105	214955	A Phase 1/2 dose Escalation and Expansion Study to Investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with Fulvestrant in subjects with ER+ breast cancer	27/10/2016	08/03/2017			31/05/2017		01/06/2017		No	Neither
49	17/EE/0205	224373	A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma	16/11/2016	15/03/2017							Site Not Confirmed	Neither
50	17/EM/0063	213979	A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission	13/10/2016	15/03/2017	27/04/2017		23/05/2017		02/06/2017		No	Sponsor

51	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease		16/03/2017			16/03/2017		16/03/2017	06/04/2017	Yes	
52	16/SC/0657	182046	A Phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with Diffuse Large B-cell Lymphoma (DLBCL)	20/03/2017	22/03/2017	28/02/2017		23/05/2017		23/05/2017	24/07/2017	No	Sponsor
53	17/YH/0050	207335	An Evaluation of Mindfulness Based Stress Reduction Groups for Adolescents and Young Adults with Crohn's disease and Ulcerative Colitis	16/02/2017	24/03/2017	02/03/2017		11/04/2017		12/04/2017	25/04/2017	Yes	
54	16/NE/0279	198051	Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	04/01/2017	24/03/2017			11/04/2017		11/04/2017	16/05/2017	Yes	
55	17/WM/0017	201600	A randomised placebo-controlled trial of mifepristone and misoprostol versus misoprostol alone in the medical management of missed miscarriage (MifeMiso trial)	16/02/2017	11/04/2017	06/04/2017		27/06/2017		06/07/2017		No	Sponsor
56	17/LO/0475	220177	The Clinical And Biological effects of the use of pRobIOtic VSL#3 in patients with oral lichen planus: a proof-of-concept study (CABRIO)		12/04/2017	12/04/2017		18/05/2017		25/05/2017	24/08/2017	No	Sponsor

57	17/NE/0115	218417	MULTICENTER, INTERNATIONAL, DOUBLE-BLIND, TWO-ARM, RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD	16/01/2017	17/04/2017	26/05/2017		23/06/2017		14/07/2017		No	Neither
58	17/SC/0185	214076	A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström's Macroglobulinemia (WM)	10/11/2016	18/04/2017			28/07/2017		08/08/2017	22/08/2017	No	Sponsor
59	17/LO/0440	217506	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer's Disease	26/04/2017	26/04/2017	20/06/2017		21/07/2017		25/07/2017	23/08/2017	No	Sponsor
60	16/WM/0472	211270	CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma	26/04/2017	04/05/2017	14/03/2017		07/06/2017		01/08/2017		No	Neither
61	16/YH/0157	204585	PersonaLising Anal cancer radioTherapy dOse – Incorporating ACT3, ACT4 and ACT5	05/05/2017	14/09/2017							Within 70 days	
62	17/EM/0166	222665	A Phase 2a trial of Avelumab, an anti-PD-L1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	05/05/2017	04/08/2017			07/08/2017		16/08/2017		Within 70 days	

63	17/WM/0106	201079	MOTILITY: Small bowel motility quantified by cine MRI as a predictor of long term response in patients with Crohn's disease commencing biological therapy	27/01/2017	08/05/2017	28/04/2017		02/06/2017		13/06/2017	30/08/2017	No	Sponsor
64	17/EM/0155	206803	POINT: Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)	05/05/2017	09/05/2017							Site Not Confirmed	Neither
65	17/EM/0183	220783	A randomised Phase III study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral Nasal Polyposis	27/02/2017	11/05/2017			16/08/2017		23/08/2017		No	Sponsor
66	17/SC/0055	219468	A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis	09/05/2017	16/05/2017	27/03/2017		25/09/2017		28/09/2017		No	Sponsor
67	17/LO/0741	216587	Multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 inpatients with early-stage Parkinson's disease carrying a GBA mutation or other prespecified variant (DEME 33640)	19/12/2016	18/05/2017							Site Not Confirmed	Sponsor

68	16/EE/0546	210292	Barrett's Oesophagus Trial 3 (BEST3): Cluster randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care	16/05/2017	19/05/2017							Site Not Confirmed	Sponsor
69	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	13/10/2016	22/05/2017							Site Not Confirmed	Sponsor
70	17/LO/0736	225746	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy with an Open-Label Extension	27/09/2016	22/05/2017							Site Not Confirmed	Sponsor
71	17/LO/0038	182633	A Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	08/03/2017	27/06/2017							Site Not Confirmed	Sponsor
72	17/EE/0120	220317	To study the role of nicotinamide riboside in inducing mitochondrial biogenesis	08/03/2017	23/05/2017	23/05/2017						Site Not Confirmed	Neither
73	17/EM/0152	216307	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML	17/11/2016	23/05/2017			29/09/2017		29/09/2017		No	Sponsor
74	17/LO/0769	218626	Face to face structured education group versus audio-visual information in Irritable Bowel Syndrome: a randomised controlled trial	12/05/2017	25/05/2017	12/05/2017		02/06/2017		02/06/2017	20/06/2017	Yes	

75	17/YH/0181	227102	Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy	21/04/2017	30/05/2017			25/08/2017		13/09/2017	25/09/2017	No	Sponsor
76	17/NW/0312	211974	Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib	10/05/2017	01/06/2017			07/08/2017		09/08/2017		No	Sponsor
77	17/NW/0317	224142	A feasibility study to evaluate the acceptability of Krio, a food for special medical purposes (FSMP) for use in the ketogenic diet (KD) with regard to product tolerance, compliance and acceptability	30/03/2017	02/06/2017			14/08/2017		30/08/2017		No	Neither
78	17/LO/1043	226184	A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer	14/02/2017	06/06/2017							Site Not Confirmed	Sponsor
79	17/ES/0051	223060	A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-ResistantOvarian Cancer	08/06/2017	07/08/2017			28/09/2017		28/09/2017		No	Sponsor

80	17/LO/0494	224195	A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent ß-Thalassemia, who have a ß0/ß0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral ßA-T87Q-Globin Vector in Subjects =50 Years of Age	28/03/2017	08/06/2017	24/05/2017		28/06/2017		30/06/2017	02/08/2017	Yes	
81	17/NW/0330	222996	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	26/07/2016	12/06/2017							Site Not Confirmed	Sponsor
82	16/SC/0584	198941	A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)	12/06/2017	12/06/2017			31/08/2017		25/09/2017		No	Neither
83	17/EE/0264	228153	A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab Or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer	11/05/2017	16/06/2017			12/09/2017		18/09/2017		No	Sponsor
84	16/LO/1495	207629	Phase III mechanistic, randomised controlled trial of Stopping Perioperative Angiotensin II Converting Enzyme inhibitors and/or receptor blockers in major noncardiac surgery	15/03/2017	16/06/2017			27/07/2017		04/08/2017		No	Sponsor

85	17/LO/0427	199962	A Phase I/II Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-Paclitaxel and Placebo In Relapsed NSCLC Adenocarcinoma	05/04/2017	20/06/2017							Site Not Confirmed	Sponsor
86	17/LO/0893	211137	A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	03/02/2017	26/06/2017							Site Not Confirmed	Sponsor
87	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or without anaemia)	12/01/2017	13/01/2017			18/07/2017		27/07/2017		No	Sponsor
88	16/NE/0418	211187	A phase III, multicentre randomised controlled trial to determine the efficacy of Robot assisted radical cystectomy (RARC) and intracorporeal urinary diversion by comparison to Open radical cystectomy (ORC) in patients with bladder cancer.	23/09/2016	25/01/2017	25/01/2017		17/02/2017		17/02/2017	21/03/2017	Yes	
89	17/LO/0048	216896	A Phase I Dose Escalation, Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	12/01/2017	31/03/2017	26/04/2017						Site Not Confirmed	Sponsor
90	17/LO/0001	211800	A Phase 1/2 , Open-Label and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency	13/09/2016	16/02/2017			23/08/2017		23/08/2017		No	Sponsor

91	16/WM/0501	185601	A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer	28/02/2017	01/03/2017	28/02/2017		11/09/2017		20/09/2017		No	Sponsor
92	17/LO/0640	204303	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)	20/10/2016	04/04/2017	04/08/2017		25/08/2017		11/09/2017		No	Sponsor
93	17/EE/0128	222308	A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factor	06/02/2017	10/04/2017	19/05/2017		07/08/2017		09/08/2017	08/03/2017	No	Sponsor
94	17/YH/0076	208944	Controlling and Lowering Blood Pressure with the MobiusHD™ – Defining Efficacy Markers	25/08/2016	19/06/2017	18/05/2017		22/06/2017		21/07/2017		No	Sponsor
95	17/NW/0228	222219	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma	18/04/2017	08/06/2017							Site Not Confirmed	Sponsor

96	17/LO/0627	218496	A Three-month, Randomized, Parallel Active Control, Single and Repeat Dose, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Delivered Intravenously (IV) in Ambulatory and Ventilator-free Patients with Late-Onset GSD-II (Pompe Disease)	09/01/2017	11/05/2017	19/06/2017						Site Not Confirmed	Sponsor
97	14/LO/2129	163516	VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot	26/04/2017	27/06/2017			25/08/2017		25/08/2017		No	Sponsor
98	17/LO/0372	220433	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation	10/03/2017	15/03/2017			17/05/2017		20/07/2017	11/08/2017	No	NHS Provider
99	17/LO/0959	223644	An acceptability, feasibility and Pilot trial: Can virtual reality prepare children for ambulatory surgery?	30/06/2017	01/07/2017	30/06/2017		06/07/2017		06/07/2017	14/07/2017	Yes	
100	14/LO/0187	143913	A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FGF/FGFR-RELATED ABNORMALITIES	10/07/2017	04/07/2017							Site Not Confirmed	Sponsor

101	17/LO/0812	226255	A Single-arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 Followed by Consolidation with Anti PD1 Antibody in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma	10/04/2017	06/07/2017			25/08/2017		05/09/2017	07/09/2017	Yes	
102	16/LO/2157	217001	EFFICACY, SAFETY, AND TOLERABILITY OF FOSMETPANTOTENATE (RE-024), A PHOSPHOPANTOTHENATE REPLACEMENT THERAPY, IN PATIENTS WITH PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION (PKAN)	29/09/2016	10/07/2017	13/07/2017						Site Not Confirmed	Sponsor
103	17/NW/0168	218752	Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response.	10/02/2017	11/07/2017	01/06/2017		09/08/2017		11/08/2017		No	Neither
104	17/LO/0506	220370	A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed Refractory B-cell Acute Lymphoblastic Leukaemia.	10/07/2017	12/07/2017	05/07/2017		20/09/2017		26/09/2017		No	Neither

105	17/NE/0234	228388	MK3475-629 – a Phase 2 Open-Label, Single arm study to evaluate the safety and efficacy of Pembrolizumab in participants with recurrent or metastatic cutaneous squamous cell carcinoma	24/07/2017	25/07/2017							Within 70 days	
106	17/EE/0291	203703	A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma	15/06/2017	31/07/2017							Within 70 days	
107	17/SC/0276	220437	A prospective randomised control trial of MAKO medial unicondylar knee arthroplasty versus Jig based Oxford unicompartmental knee arthroplasty with navigation control	17/07/2017	01/08/2017	01/08/2017		04/04/2017		15/08/2017		Within 70 days	
108	17/LO/1019	223213	A Phase I open label clinical trial evaluating the safety and anti tumor activity of autologous T cells expressing enhanced TCRs specific for alpha-fetoprotein (AFPc332 T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC)	09/02/2017	01/08/2017	15/09/2017						Within 70 days	
109	17/LO/0797	220423	A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.	28/02/2017	02/08/2017	01/08/2017						Within 70 days	
110	17/NW/0193	216411	IntAct: Intraoperative Fluorescence Angiography to Prevent Anastomotic Leak in Rectal Cancer	26/04/2017	02/08/2017							Within 70 days	
111	16/EE/0357	206501	Opicapone in clinical practice (OPTIPARK)	24/10/2016	09/08/2017	31/10/2016						Within 70 days	

112	17/LO/1055	228923	A phase IV, prospective, randomised single-blind UK multicentre trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP	06/06/2017	10/08/2017	01/08/2017		31/08/2017		01/09/2017		Within 70 days	
113	17/LO/1060	187783	RANDOMISED DOUBLE-BLIND EFFICACY AND MECHANISM STUDY OF SUB-SENSORY SACRAL (OPTIMISED) NEUROMODULATION IN ADULTS WITH FAECAL INCONTINENCE	10/08/2017	10/08/2017							Within 70 days	
114	17/ES/0040	223878	A Phase III, Multicentre, Randomised, Placebo-controlled study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in combination with Platinum-Based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma	07/08/2017	11/08/2017							Within 70 days	
115	17/LO/1306	228268	A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation (REACH 3)	27/07/2017	14/08/2017							Within 70 days	
116	17/LO/1273	216265	A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma		15/08/2017							Within 70 days	

117	17/LO/1367	225049	A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.	25/05/2017	16/08/2017							Within 70 days	
118	17/LO/0117	217367	Immunotherapy for high risk/relapsed CD19+ Acute Lymphoblastic Leukaemia using CAR T cells to target CD19	09/08/2017	18/08/2017							Within 70 days	
119	17/LO/0738	213614	Evaluation of an interdisciplinary performance arts intervention that combines movement and voice to reduce anxiety and depression among those living with the effects of a stroke.	31/08/2017	01/09/2017			13/09/2017				Within 70 days	
120	17/EE/0384	218262	A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BSC) compared to Placebo plus BSC in Patients with Advanced or Metastatic Gastric Cancer (GC)	07/02/2017	04/09/2017							Within 70 days	
121	17/EM/0217	200797	Investigation of SpaCEOAR for Men with High Risk Prostate CAncer treated with HDR Brachytherapy boost and ExterNal Beam Radiotherapy (ICEMAN)		06/09/2017			12/09/2017		12/09/2017		Within 70 days	

122	17/LO/1458	204582	An investigation of the parent-observed link between behaviour symptoms and the dietary management of gastrointestinal symptoms in children with autism spectrum disorder. Can gastrointestinal symptoms be managed by dietary intervention and does this bring benefits to children with autism spectrum disorder (ASD) and their families, over and above improvement in gastrointestinal (GI) symptoms?	22/08/2017	06/09/2017							Within 70 days	
123	17/LO/0693	226490	An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of Study CRAD001M2304 (EXIST3)	27/06/2017	19/09/2017			25/09/2017		27/09/2017		Within 70 days	
124	16-LO-0994	204296	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC)		19/09/2017							#N/A	
125	16/YH/0491	203984	Surveillance of invasive Listeria infections in infants under 90 days of age	14/09/2017	16/09/2017							Within 70 days	

126	17/EE/0016	206408	A Randomised Clinical Trial Of Manual versus trajectory guided Stereoelectroencephalography Electrode Placement	16/08/2017	25/09/2017							Within 70 days	
127	16/EM/0324	204032	A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects with Alzheimer's Disease	20/07/2017	25/09/2017							Within 70 days	
128	17/ES/0107	231506	A Phase 2 single arm study of Safety and Efficacy of Coversin in adult aHUS subjects	20/07/2017	26/09/2017	14/09/2017						Within 70 days	

Delivering Clinical Research

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	15/EE/0460	193953	Evaluation of a Novel Electronic Transanal Irrigation System - Navina Smart	Number Agreed	16	16	Not Available / Not Agreed			01/10/2016	16	Recruitment Finished

2	14/SC/1167	144247	Phase 3, Randomised, PlaceboControlled, Doubleblind, MultiCentre, TwoPart Study of Patritumab (U31287) in Combination with Erlotinib in EGFR Wildtype Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at	Number Agreed	5	5	Date Agreed	31/10/2014	2	06/11/2016	2	Withdrawn By Sponsor
3	14/NE/1175	164135	Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)	Number Agreed	2	2	Date Agreed	01/06/2016	0	08/11/2016	0	Withdrawn By Sponsor
4	13/WM/0373	135259	A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease	Number Agreed	3	3	Date Agreed	01/06/2015	1	24/11/2016	1	Withdrawn By Sponsor
5	16/LO/0951	203461	A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS WITH LOW ADAMTS13 ACTIVITY	Number Agreed	2	2	Not Available / Not Agreed			27/12/2016	2	Withdrawn By Sponsor
6	15/LO/0681	174407	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients with Early Manifest Huntington's Disease	Number Agreed	6	6	Date Agreed	01/11/2015	6	22/02/2017	6	Recruitment Finished
7	15/LO/0009	146896	A Prospective Development Study evaluating Focal Therapy using Encage? Coiled Bipolar Radiofrequency Ablation in Men with Localised Prostate Cancer	Number Agreed	20	20	Not Available / Not Agreed			28/02/2017	23	Recruitment Finished
8	15/LO/1500	187068	Investigation of drug-drug interaction between nintedanib and pirfenidone in patients with IPF (an open label, multiple-dose, two group study)	Number Agreed	2	2	Date Agreed	01/07/2016	3	14/03/2017	3	Recruitment Finished

9	14/SC/1340	17797	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease	Number Agreed	10	10	Date Agreed	27/11/2015	10	05/04/2017	10	Recruitment Finished
10	16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	3	3	Not Available / Not Agreed			10/04/2017	8	Recruitment Finished
11	14/SC/1340	151325	A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease	Number Agreed	7	7	Date Agreed	27/11/2015	10	21/04/2017	10	Recruitment Finished
12	13/EM/0373	15394	An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma	Number Agreed	3	3	Date Agreed	01/01/2015	1	25/04/2017	1	Recruitment Finished
13	15/LO/1441	186018	A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura	Number Agreed	18	18	Date Agreed	01/11/2017	18	29/04/2017	18	Recruitment Finished
14	15/LO/1441	186018	A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura	Number Agreed	3	3	Not Available / Not Agreed			29/04/2017	18	Recruitment Finished
15	15/EM/0454	184386	An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus	Number Agreed	24	24	Date Agreed	01/06/2016	24	04/05/2017	24	Recruitment Finished

16	16/LO/0334	193988	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	2	2	Date Agreed	01/05/2017	2	05/05/2017	2	Recruitment Finished
17	16/NE/0027	187317	A phase 3, multicenter, randomized, open-label study of avelumab (MSB0010718C) alone or in combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum resistant/refractory ovarian cancer	Number Agreed	3	3	Date Agreed	01/11/2016	23	15/05/2017	23	Recruitment Finished
18	15/LO/0443	172123	A PHASE 3, MULTICENTER,RANDOMIZED, OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Number Agreed	6	6	Not Available / Not Agreed			15/05/2017	5	Recruitment Finished
19	14/LO/1597	158625	A Randomized, Double-Blind, Placebo-Controlled, Four-Arm,Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect on Quality of Life of Human Recombinant Alkaline Phospha	Number Agreed	5	5	Date Agreed	01/01/2016	12	18/05/2017	12	Recruitment Finished
20	15/WM/0457	195511	An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor a	Number Agreed	5	5	Date Agreed	01/09/2016	7	18/05/2017	7	Recruitment Finished
21	16/LO/1450	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Na?ve to Proteasome Inhibitors	Number Agreed	4	4	Date Agreed	30/06/2018	5	19/05/2017	5	Recruitment Finished

22	15/SW/0220	182750	A Phase 3, Multicentre, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Axial Nonradiographic Spondyloarthritis	Number Agreed	3	3	Date Agreed	17/07/2017	1	02/07/2017	1	Withdrawn By Sponsor
23	16/SW/0090	199970	Ustekinumab in Subjects with Radiographic Axial Spondyloarthritis	Number Agreed	3	3	Date Agreed	31/07/2017	1	30/05/2017	1	Withdrawn By Sponsor
24	16/SC/0341	204761	A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory Malignant Mesothelioma with BAP1 Loss of Function	Number Agreed	3	3	Date Agreed	01/10/2017	2	02/06/2017	2	Recruitment Finished
25	16/LO/1612	201997	Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)	Number Agreed	20	20	Not Available / Not Agreed			09/06/2017	17	Recruitment Finished
26	16/LO/0083	193141	A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus best supportive care versus best supportive care in adults who require regular red-blood cell transfusions due t	Number Agreed	3	3	Date Agreed	01/02/2018	5	10/06/2017	5	Recruitment Finished
27	15/LO/1670	188788	Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Patritumab (U3-1287) in Combination with Cetuximab plus Platinum-Based Therapy in First Line Setting in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Number Agreed	12	12	Date Agreed	01/04/2017	2	21/06/2017	4	Recruitment Finished
28	16/NW/0379	200426	LY2801653 and LY3009806 - Advanced or Metastatic Biliary Tract Cancer	Number Agreed	8	8	Date Agreed	01/05/2017	4	03/07/2017	4	Recruitment Finished
29	16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN AS A SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE?S DISEASE	Number Agreed	3	3	Not Available / Not Agreed			24/07/2017	1	Withdrawn By Sponsor

30	16/EM/0165	203281	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (CANC 5545)	Number Agreed	2	2	Date Agreed	22/03/2018	2	28/07/2017	2	Recruitment Finished
31	14/LO/2156	166004	A Phase 2 Proof of Concept (PoC), DoubleBlind, Randomised, Placebocontrolled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VSN16R for the treatment of spasticity in patients with Multiple Sclerosis.	Number Agreed	75	75	Not Available / Not Agreed			31/07/2017	81	Recruitment Finished
32	16/EE/0243	207331	A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study Of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease	Number Agreed	5	5	Date Agreed	31/03/2017	1	05/09/2017	1	Withdrawn By Sponsor
33	16/SC/0076	199027	A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant	Number Agreed	8	8	Not Available / Not Agreed			27/03/2017	2	Recruitment Finished